SRS Investment Management LLC Takes Position in Humana Inc. (NYSE:HUM)

SRS Investment Management LLC purchased a new position in shares of Humana Inc. (NYSE:HUM) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 123,293 shares of the insurance provider’s stock, valued at approximately $31,281,000. Humana makes up approximately 0.4% of SRS Investment Management LLC’s holdings, making the stock its 17th biggest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Humana by 15.8% during the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after buying an additional 1,751,857 shares in the last quarter. Dodge & Cox lifted its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after acquiring an additional 5,264,045 shares during the period. Pzena Investment Management LLC boosted its position in Humana by 44.0% in the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after purchasing an additional 1,103,132 shares during the last quarter. Geode Capital Management LLC grew its stake in Humana by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock valued at $729,658,000 after purchasing an additional 63,562 shares during the period. Finally, Invesco Ltd. increased its position in shares of Humana by 29.8% during the 4th quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock valued at $608,348,000 after purchasing an additional 550,692 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Down 7.0 %

Shares of NYSE:HUM opened at $246.07 on Tuesday. The company has a market cap of $29.70 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 2.05 and a beta of 0.62. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The firm has a fifty day moving average price of $265.62 and a two-hundred day moving average price of $270.27. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.44%. The ex-dividend date of this dividend is Friday, June 27th. Humana’s dividend payout ratio is currently 35.58%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. cut their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. StockNews.com upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Monday, April 7th. Morgan Stanley lowered their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Robert W. Baird upped their price objective on Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Finally, Truist Financial raised their target price on Humana from $290.00 to $325.00 and gave the stock a “hold” rating in a research report on Friday, April 11th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.